Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study With a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study With a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Posdinemab (Primary)
  • Indications Alzheimer's disease; Cognition disorders; Dementia
  • Focus Therapeutic Use
  • Acronyms Autonomy
  • Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

  • 08 Jan 2025 According to Johnson & Johnson media release, company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, being investigated to treat patients with early Alzheimers disease.
  • 01 Aug 2024 Trial design presented at the Alzheimer's Association International Conference 2024.
  • 18 Jun 2024 Planned primary completion date changed from 28 Nov 2025 to 27 Feb 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top